CN120168449A - 苏糖酸镁组合物及其用途 - Google Patents
苏糖酸镁组合物及其用途 Download PDFInfo
- Publication number
- CN120168449A CN120168449A CN202510100404.6A CN202510100404A CN120168449A CN 120168449 A CN120168449 A CN 120168449A CN 202510100404 A CN202510100404 A CN 202510100404A CN 120168449 A CN120168449 A CN 120168449A
- Authority
- CN
- China
- Prior art keywords
- dosage form
- magnesium
- threonate
- day
- lbm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662756P | 2018-04-25 | 2018-04-25 | |
| US62/662,756 | 2018-04-25 | ||
| PCT/US2019/028903 WO2019209943A1 (en) | 2018-04-25 | 2019-04-24 | Magnesium threonate compositions and uses thereof |
| CN201980042120.9A CN112384210A (zh) | 2018-04-25 | 2019-04-24 | 苏糖酸镁组合物及其用途 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980042120.9A Division CN112384210A (zh) | 2018-04-25 | 2019-04-24 | 苏糖酸镁组合物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN120168449A true CN120168449A (zh) | 2025-06-20 |
Family
ID=68291941
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510100404.6A Pending CN120168449A (zh) | 2018-04-25 | 2019-04-24 | 苏糖酸镁组合物及其用途 |
| CN202510100476.0A Pending CN120241690A (zh) | 2018-04-25 | 2019-04-24 | 苏糖酸镁组合物及其用途 |
| CN201980042120.9A Pending CN112384210A (zh) | 2018-04-25 | 2019-04-24 | 苏糖酸镁组合物及其用途 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510100476.0A Pending CN120241690A (zh) | 2018-04-25 | 2019-04-24 | 苏糖酸镁组合物及其用途 |
| CN201980042120.9A Pending CN112384210A (zh) | 2018-04-25 | 2019-04-24 | 苏糖酸镁组合物及其用途 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11717501B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3784227A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2021522344A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20210005662A (cg-RX-API-DMAC10.html) |
| CN (3) | CN120168449A (cg-RX-API-DMAC10.html) |
| AU (2) | AU2019261406A1 (cg-RX-API-DMAC10.html) |
| BR (1) | BR112020021812A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3098360A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2019209943A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3784227A4 (en) | 2018-04-25 | 2022-03-02 | Neurocentria, Inc. | MAGNESIUM THREONATE COMPOSITIONS AND THEIR USES |
| WO2021245697A1 (en) | 2020-06-01 | 2021-12-09 | Celagenex Research (India) Pvt. Ltd. | Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling |
| KR20230058095A (ko) * | 2020-08-28 | 2023-05-02 | 디에프아이 유에스에이, 엘엘씨. | L-크실론산으로부터 l-트레온산 염을 생산하는 방법 |
| CN115047058A (zh) * | 2021-03-09 | 2022-09-13 | 江苏开元药业有限公司 | 一种测定铝碳酸镁咀嚼片溶出曲线的方法 |
| CN114304610A (zh) * | 2021-12-24 | 2022-04-12 | 苏州麦轮生物科技有限公司 | 一种含有苏糖酸镁的营养补充剂及其应用 |
| WO2024232931A1 (en) * | 2023-05-11 | 2024-11-14 | Yon Doo Ough | Apparatus and method for contact free delivery and administration of magnesium as a drug |
| CN119504413A (zh) * | 2025-01-20 | 2025-02-25 | 浙江天启生化股份有限公司 | 一种l-苏糖酸镁合成方法及应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6010718A (en) * | 1997-04-11 | 2000-01-04 | Abbott Laboratories | Extended release formulations of erythromycin derivatives |
| GB0009522D0 (en) * | 2000-04-19 | 2000-06-07 | Smithkline Beecham Plc | Composition |
| DK1524981T3 (da) * | 2002-07-29 | 2009-06-22 | Glaxo Group Ltd | Sammensætninger med vedvarende frigivelse indeholdende lamotrigin |
| AU2008227465B2 (en) * | 2007-03-22 | 2014-02-06 | Magceutics, Inc. | Magnesium compositions and uses thereof |
| US8142803B2 (en) * | 2007-03-22 | 2012-03-27 | Magceutics, Inc. | Magnesium compositions and uses thereof for neurological disorders |
| WO2011003045A1 (en) * | 2009-07-01 | 2011-01-06 | Magceutics, Inc. | Slow release magnesium composition and uses thereof |
| US9943489B2 (en) * | 2010-02-03 | 2018-04-17 | Pharmatwob Ltd. | Extended release formulations of rasagiline and uses thereof |
| CN108289875A (zh) | 2015-09-11 | 2018-07-17 | 纽罗森特里亚股份有限公司 | 苏糖酸盐化合物及其使用方法 |
| CN105326855A (zh) | 2015-10-27 | 2016-02-17 | 南京大学 | 易吸收复合夹层式螯合镁钙片 |
| CN105326955B (zh) * | 2015-11-02 | 2019-04-12 | 北京市眼科研究所 | 一种治疗睑缘炎的组合物及其制备方法 |
| US10617713B2 (en) | 2016-03-08 | 2020-04-14 | Neurocentria, Inc. | Methods of modifying neuronal function by changing intracellular magnesium levels |
| CN107625776A (zh) | 2016-07-19 | 2018-01-26 | 无锡脑镁素生物医药科技有限公司 | 用于改善睡眠的镁组合物及其用途 |
| CN106360734A (zh) | 2016-09-28 | 2017-02-01 | 张家港威胜生物医药有限公司 | 一种同时具有减肥和美容作用的组合物及其制备方法与用途 |
| WO2018200885A1 (en) | 2017-04-26 | 2018-11-01 | Neurocentria, Inc. | Magnesium compositions and methods of use |
| EP3784227A4 (en) | 2018-04-25 | 2022-03-02 | Neurocentria, Inc. | MAGNESIUM THREONATE COMPOSITIONS AND THEIR USES |
-
2019
- 2019-04-24 EP EP19792918.5A patent/EP3784227A4/en active Pending
- 2019-04-24 CN CN202510100404.6A patent/CN120168449A/zh active Pending
- 2019-04-24 US US16/393,298 patent/US11717501B2/en active Active
- 2019-04-24 WO PCT/US2019/028903 patent/WO2019209943A1/en not_active Ceased
- 2019-04-24 CN CN202510100476.0A patent/CN120241690A/zh active Pending
- 2019-04-24 JP JP2021509954A patent/JP2021522344A/ja active Pending
- 2019-04-24 BR BR112020021812-0A patent/BR112020021812A2/pt unknown
- 2019-04-24 KR KR1020207033637A patent/KR20210005662A/ko active Pending
- 2019-04-24 CA CA3098360A patent/CA3098360A1/en active Pending
- 2019-04-24 CN CN201980042120.9A patent/CN112384210A/zh active Pending
- 2019-04-24 AU AU2019261406A patent/AU2019261406A1/en not_active Abandoned
-
2023
- 2023-06-15 US US18/210,515 patent/US20240156761A1/en active Pending
-
2024
- 2024-10-11 JP JP2024178890A patent/JP2025011238A/ja active Pending
-
2025
- 2025-02-27 AU AU2025201393A patent/AU2025201393A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019261406A1 (en) | 2020-12-17 |
| US11717501B2 (en) | 2023-08-08 |
| US20240156761A1 (en) | 2024-05-16 |
| US20190328689A1 (en) | 2019-10-31 |
| EP3784227A1 (en) | 2021-03-03 |
| AU2025201393A1 (en) | 2025-03-20 |
| CN112384210A (zh) | 2021-02-19 |
| JP2021522344A (ja) | 2021-08-30 |
| CN120241690A (zh) | 2025-07-04 |
| EP3784227A4 (en) | 2022-03-02 |
| WO2019209943A1 (en) | 2019-10-31 |
| KR20210005662A (ko) | 2021-01-14 |
| JP2025011238A (ja) | 2025-01-23 |
| BR112020021812A2 (pt) | 2021-02-23 |
| CA3098360A1 (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN120241690A (zh) | 苏糖酸镁组合物及其用途 | |
| TWI241911B (en) | Sustained release ranolazine formulations | |
| CN104379138B (zh) | 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合 | |
| US10555907B2 (en) | Controlled-release solid dosage forms of mesalamine | |
| EP2623099A1 (en) | Composition and method for treating neurological disease | |
| EP1942875B1 (en) | Controlled release formulation | |
| US20120039954A1 (en) | Method of treating insomnia | |
| JPH0696524B2 (ja) | バルプロ酸をベ−スとした新規薬剤組成物及びその製法 | |
| CN104902880B (zh) | 包含氢吗啡酮和纳洛酮的药物组合物 | |
| JPH07558B2 (ja) | モピダモール製剤 | |
| TWI841539B (zh) | 雙層醫藥錠劑調配物 | |
| EP1814529B1 (en) | Dosage form time-lagged of drugs for the therapy of insomnia | |
| US20180015080A1 (en) | Compositions and methods for treatment in parkinson's disease patients | |
| KR101277021B1 (ko) | 위체류 약물 전달시스템을 이용한 경구용 방출제어형 레바미피드-함유 이층정 제제 및 그 제조방법 | |
| JP2665858B2 (ja) | 持効性塩酸オキシブチニン製剤 | |
| TW200800155A (en) | Gastric retentive gabapentin dosage forms and methods for using same | |
| TW202313072A (zh) | 檸檬酸鐵之兒科調配物 | |
| TWI764159B (zh) | 口服組合物、製造方法及其用途 | |
| JPH07101867A (ja) | 制酸剤組成物およびそれを用いた医薬組成物 | |
| CN121910679A (zh) | 一种包含速释递送组合物和缓释递送组合物的组合及其制备方法和用途 | |
| JP2011068614A (ja) | ビタミン製剤 | |
| HK1107282B (en) | Dosage form time-lagged of drugs for the therapy of insomnia | |
| WO2007010508A2 (en) | Controlled release compositions of metaxalone | |
| JP2009256237A (ja) | 固形製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |